📈 Fed's first cut since 2020: Time to buy the dip? See Tech-focused stock picksUnlock AI Picks

Mendus AB (IMMUN)

Stockholm
Currency in SEK
Disclaimer
8.098
+0.018(+0.22%)
Real-time Data
IMMUN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
7.7328.100
52 wk Range
6.69016.380
Bid/Ask
7.767 / 8.098
Prev. Close
8.08
Open
7.803
Day's Range
7.732-8.1
52 wk Range
6.69-16.38
Volume
8,716
Average Volume (3m)
38,216
1-Year Change
-5.5%
Fair Value
Unlock
Fair Value Upside
Unlock
IMMUN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Mendus AB Company Profile

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies. It has an alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel; and the Australasian Leukaemia and Lymphoma Group to expand the clinical development of vididencel as a maintenance treatment for AML. The company has a collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.

Compare IMMUN to Peers and Sector

Metrics to compare
IMMUN
Peers
Sector
Relationship
P/E Ratio
−2.9x−2.3x−0.6x
PEG Ratio
−0.04−0.030.00
Price/Book
0.6x2.3x2.6x
Price / LTM Sales
12.9x16.3x3.1x
Upside (Analyst Target)
345.5%110.6%57.2%
Fair Value Upside
Unlock16.6%7.3%Unlock

FAQ

What Is the Mendus AB (IMMUN) Stock Price Today?

The Mendus AB stock price today is 8.098

What Stock Exchange Does Mendus AB Trade On?

Mendus AB is listed and trades on the Stockholm stock exchange.

What Is the Stock Symbol for Mendus AB?

The stock symbol for Mendus AB is "IMMUN."

What Is the Mendus AB Market Cap?

As of today, Mendus AB market cap is 407.81M.

What is Mendus AB Earnings Per Share?

The Mendus AB EPS is -3.41.

What Is the Next Mendus AB Earnings Date?

Mendus AB will release its next earnings report on Nov 08, 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.